Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilization and outcomes of COVID-19 positive donors in pediatric kidney transplantation-a population-based study.

Pediatric nephrology (Berlin, Germany)·2026
Same author

A Chatbot to Meet Parents' Information Needs for Sickle Cell Trait Newborn Screening Results: Multiple Methods Formative Study.

Journal of medical Internet research·2026
Same author

Cost avoidance analysis of outpatient parenteral antimicrobial therapy (OPAT) plan reconciliation for patients enrolled in value-based payment models at an academic hospital.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

A Qualitative Study on Parental Experiences with Genetic Counseling After a Positive Newborn Screen for Recently Added Conditions on the Recommended Uniform Screening Panel (RUSP).

International journal of neonatal screening·2025
Same author

Heart-kidney transplants linked to better outcomes compared to heart-only transplants in children with non-dialysis-dependent advanced chronic kidney disease.

Pediatric nephrology (Berlin, Germany)·2025
Same author

Expanding the Phenotype Spectrum of β-Mannosidosis.

Neurology. Genetics·2025

Related Experiment Video

Updated: Mar 29, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

13.7K

Beyond Detection: Comparing State-Based Newborn Screening Methods for Effective Mucopolysaccharidosis I Diagnosis.

Rithika Thampy1, Nishitha R Pillai2, Michael Evans3

  • 1Robbins College of Health and Human Sciences, Baylor University, Waco, TX 76706, USA.

International Journal of Neonatal Screening
|March 27, 2026
PubMed
Summary

Second-tier glycosaminoglycan (GAG) analysis in newborn screening for Mucopolysaccharidosis type I (MPS I) improves detection of severe cases and reduces false positives. However, it shows minimal impact on pseudodeficiency detection and comparable rates for attenuated MPS I cases.

Keywords:
MPS Iglycosaminoglycansnewborn screening

More Related Videos

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines
12:06

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines

Published on: November 25, 2017

13.5K
Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

14.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

13.7K
Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines
12:06

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines

Published on: November 25, 2017

13.5K
Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

14.3K

Area of Science:

  • Biochemistry and Metabolic Disorders
  • Genetics and Genomics
  • Public Health and Newborn Screening

Background:

  • Mucopolysaccharidosis type I (MPS I) is a rare genetic disorder characterized by glycosaminoglycan (GAG) accumulation.
  • MPS I screening is crucial for differentiating severe (Hurler syndrome) from attenuated (Scheie, Hurler-Scheie syndromes) forms.
  • The Recommended Uniform Screening Panel (RUSP) included MPS I in 2016, with widespread adoption in US newborn screening (NBS) programs.

Purpose of the Study:

  • To evaluate the impact of second-tier GAG analysis on the diagnostic outcomes of MPS I newborn screening.
  • To compare the detection rates of severe, attenuated, false-positive, and pseudodeficiency cases between NBS programs with and without second-tier GAG analysis.
  • To assess the effectiveness of second-tier GAG analysis in mitigating false positives and improving diagnostic resolution.

Main Methods:

  • A nationwide survey of US NBS programs was conducted to collect data on MPS I screening.
  • Data included total screen-positive results, final diagnostic outcomes (false-positive, pseudodeficiency, severe MPS I, attenuated MPS I, undetermined phenotype), and testing methodologies.
  • Responses from 32 NBS programs were analyzed, comparing cohorts with and without second-tier blood spot GAG determinations.

Main Results:

  • Programs using second-tier GAG analysis detected a higher proportion of severe MPS I cases (48% vs. 29%).
  • The proportion of attenuated MPS I cases remained consistent across both groups (13% vs. 14%).
  • Second-tier GAG analysis slightly reduced pseudodeficiency detection (85% vs. 91%) and false positives, but the difference in pseudodeficiency was marginal.

Conclusions:

  • Second-tier GAG analysis enhances the detection of severe MPS I cases and reduces false positives in newborn screening.
  • While effective for severe forms, the impact on pseudodeficiency detection is minimal, and attenuated case detection remains comparable.
  • The higher rate of 'undetermined phenotype' cases in the second-tier cohort warrants further investigation for long-term diagnostic clarity.